ReviewPharmacogenomics2017
Promising pharmacogenetic targets for treating alcohol use disorder: evidence from preclinical models.
Review in Pharmacogenomics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 20 citations in OpenAlex.
- Epigenetic Landscapes of Methamphetamine Addiction: Unravelling the Diagnostic Potential of Gene Methylation.Addiction biology · 2025Article
- Influence of Inherited Seizure Susceptibility on Intermittent Voluntary Alcohol Consumption and Alcohol Withdrawal Seizures in Genetically Epilepsy-Prone Rats (GEPR-3s).Brain sciences · 2024Article
- BK ZERO isoform HEK293 stably transfected cell lines differing 3'UTRs to assess miR-9 regulation.PloS one · 2024Article
- Cross-species epigenetic regulation of nucleus accumbens KCNN3 transcripts by excessive ethanol drinking.Translational psychiatry · 2023Article
- Kv7 Channels and Excitability Disorders.Handbook of experimental pharmacology · 2021Article
- Bioinformatics identification and pharmacological validation of Kcnn3/KTranslational psychiatry · 2020Article
- Downregulation of M-channels in lateral habenula mediates hyperalgesia during alcohol withdrawal in rats.Scientific reports · 2019Article
- Pharmacogenetics of alcohol addiction: current perspectives.The application of clinical genetics · 2019Article
- Psoriasis and alcohol.Psoriasis (Auckland, N.Z.) · 2019Article
- Identification and validation of midbrain Kcnq4 regulation of heavy alcohol consumption in rodents.Neuropharmacology · 2018Article
- BK channels and alcohol tolerance: Insights from studies onMedicine internationalArticle
- Chronic Alcohol, Intrinsic Excitability, and Potassium Channels: Neuroadaptations and Drinking Behavior.Handbook of experimental pharmacologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Inherited genetic variants contribute to risk factors for developing an alcohol use disorder, and polymorphisms may inform precision medicine strategies for treating alcohol addiction. Targeting genetic mutations linked to alcohol phenotypes has provided promising initial evidence for reducing relapse rates in alcoholics. Although successful in some studies, there are conflicting findings and the reports of adverse effects may ultimately limit their clinical utility, suggesting that novel pharmacogenetic targets are necessary to advance precision medicine approaches. Here, we describe promising novel genetic variants derived from preclinical models of alcohol consumption and dependence that may uncover disease mechanisms that drive uncontrolled drinking and identify novel pharmacogenetic targets that facilitate therapeutic intervention for the treatment of alcohol use disorder.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.